Gapping up
In reaction to strong earnings/guidance:
- ELF +18.9%, AFI +15.1%, FN +12.8%, CVGI +12.8%, VCEL +11.6%, MNK +10.5%, NIO +10.2%, ONDK +10.1%, AAC +9%, MYL +8.6%, APPS +8.6%, ATUS +8.4%, MTW +8%, BLD +7.8%, LASR +7.5%, BKNG +6.9%, GOGO +6.2%, BKD +6%, RNG +5.4%, EYPT +4.8%, LPX +4.3%, MOS +4%, ELAN +3.8%, CVS +3.8%, AGEN +3.7%, ACHC +3.5%, NTR +3.3% (also increases quarterly dividend; decided to permanently close New Brunswick potash facility following strategic review of its potash portfolio), P +2.9%, BHC +2.9%, ATRA +2.5%, CRZO +2.1%, GTN +1.7%, ALLT +1.5%, REGN +1.4%, USFD +1.4%, APLE +1.2%, TRTX +1.1%, GOLD +1.1%, AFIN +1%, MBUU +1%
Other news:
- EYPT +4.8% (EyePoint Pharmaceuticals and Ocumension Therapeutics announce exclusive license agreement for the development and commercialization of EyePoint's three-year micro insert using Durasert technology)
- CLVS +4.5% (Armistice Capital last night disclosed a 9.8% active stake)
- AXL +2.5% (Chairman/CEO disclosed the purchase of ~88K shares worth ~$1 mln)
- SYMC +2.2% (extending today's move higher)
- EXPE +2.1% (following BKNG results)
- MAXR +1% (signs three-year extension of its existing EnhancedView Service Level Agreement (SLA) with the U.S. National Reconnaissance Office)
- AVEO +0.8% (announces 'positive' top line results from the primary analysis of the TIVO-3 trial)
Analyst comments:
- DRNA +4.3% (upgraded to Buy at Goldman)
- SQ +1.9% (upgraded to Buy at Citigroup)
![]()